Zhao Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhao Wei has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Zhibing Zheng
National Engineering Research Center for the Emergency Drug
8 shared publications Yan-Qin Liu
Department of Military Toxicology and Biochemical Pharmacology, Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China
4 shared publicationsYong-An Wang
Department of Military Toxicology and Biochemical Pharmacology, Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China
4 shared publicationsHuanglei Bi
Department of Pharmacy, The 969th Hospital of the joint logistics support force of PLA, Hohhot 010051, China
3 shared publicationsHui-Fang Nie
Department of Medicinal Chemistry, School of Pharmacy, Air Force Medical University, Xi'an 710032, China
3 shared publicationsLin Yao
Department of Medicinal Chemistry, School of Pharmacy, Fourth Military Medical University, Xi'an, 300071, China
3 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Springer Nature in BMC Medical Genomics
- Vol. 19 (1)
Targeting acetylcholine: a novel strategy for treating lung adenocarcinoma
Background: Lung cancer remains one of the deadliest cancers, both in terms of the incidence and mortality rates. Although a combination therapy comprising immune checkpoint inhibitors and chemotherapy has become the standard therapy for driver gene-negative lung adenocarcinoma, its efficacy is yet to be further improved. Additionally, new treatment methods still need to be developed. Acetylcholinesterase (AChE) has emerged as a potential therapeutic target in various cancers. However, its role in lung adenocarcinoma remains poorly understood. Objective: This study aims to investigate the role of AChE in the progression of lung adenocarcinoma and to design and synthesize small-molecule compounds targeting AChE for exploring their potential as novel therapeutic agents. Methods: AChE is significantly overexpressed in lung adenocarcinoma. Therefore, we synthesized two novel AChE inhibitors and characterized them by nuclear magnetic resonance and high-resolution mass spectrometry. Subsequently, two inhibitors were added to lung adenocarcinoma A549 and H1975 cells to detect changes in their biological behaviors such as cell proliferation, apoptosis, cell cycle, and colony-formation ability. Simultaneously, a mouse transplant tumor model was constructed and an AChE inhibitor was injected intraperitoneally to observe changes in the volume and weight of the mouse transplant tumor. Result: Our AChE inhibitors showed significant cytotoxicity against A549 and H1975 cells. They can effectively inhibit cell proliferation, induce apoptosis, prevent cell cycle progression, and reduce colony-formation ability. The mouse transplant tumor model confirmed that they can inhibit cell proliferation. The tumor volume and weight were significantly reduced in the intraperitoneal injection inhibitor group. Notably, the inhibitor did not cause pathological damage to normal organs. Conclusion: Our novel AChE inhibitors can potentially be used to treat lung adenocarcinoma and to develop a promising new direction for future lung adenocarcinoma treatments.
- 3 July 2026
- Published by Springer Nature in BMC Medical Genomics
- Vol. 19 (1)
Open AccessTargeting acetylcholine: a novel strategy for treating lung adenocarcinoma
Background: Lung cancer remains one of the deadliest cancers, both in terms of the incidence and mortality rates. Although a combination therapy comprising immune checkpoint inhibitors and chemotherapy has become the standard therapy for driver gene-negative lung adenocarcinoma, its efficacy is yet to be further improved. Additionally, new treatment methods still need to be developed. Acetylcholinesterase (AChE) has emerged as a potential therapeutic target in various cancers. However, its role in lung adenocarcinoma remains poorly understood. Objective: This study aims to investigate the role of AChE in the progression of lung adenocarcinoma and to design and synthesize small-molecule compounds targeting AChE for exploring their potential as novel therapeutic agents. Methods: AChE is significantly overexpressed in lung adenocarcinoma. Therefore, we synthesized two novel AChE inhibitors and characterized them by nuclear magnetic resonance and high-resolution mass spectrometry. Subsequently, two inhibitors were added to lung adenocarcinoma A549 and H1975 cells to detect changes in their biological behaviors such as cell proliferation, apoptosis, cell cycle, and colony-formation ability. Simultaneously, a mouse transplant tumor model was constructed and an AChE inhibitor was injected intraperitoneally to observe changes in the volume and weight of the mouse transplant tumor. Result: Our AChE inhibitors showed significant cytotoxicity against A549 and H1975 cells. They can effectively inhibit cell proliferation, induce apoptosis, prevent cell cycle progression, and reduce colony-formation ability. The mouse transplant tumor model confirmed that they can inhibit cell proliferation. The tumor volume and weight were significantly reduced in the intraperitoneal injection inhibitor group. Notably, the inhibitor did not cause pathological damage to normal organs. Conclusion: Our novel AChE inhibitors can potentially be used to treat lung adenocarcinoma and to develop a promising new direction for future lung adenocarcinoma treatments.
- Open Access
Tetrahydrocarbazole as a Versatile Scaffold in Drug Discovery: A Cross-Target SAR Analysis and Design Paradigms
Tetrahydrocarbazole (THCz) is a privileged scaffold validated by clinically approved drugs such as ondansetron, frovatriptan, and ramatroban and exhibits diverse bioactivities including antimicrobial, antitumor, antidiabetic, and neuroprotective effects. Despite extensive structure–activity relationship (SAR) studies, a systematic integration of findings across different therapeutic targets has been lacking. This review provides a comprehensive SAR dissection of THCz derivatives across key targets (bacterial sliding clamp, BTK, HDAC, AMPK, etc.), analyzing how modifications at key positions of the core scaffold (N-9, C-1, and C-6) influence potency and selectivity. Notably, we highlight four emerging design paradigms: pharmacophore hybridization, conformational constraint, cross-target SAR decoding, and precision intervention. By consolidating fragmented knowledge into a practical cross-target SAR matrix, this review offers a strategic framework for the rational design of next-generation THCz-based therapeutics.
Open AccessTetrahydrocarbazole as a Versatile Scaffold in Drug Discovery: A Cross-Target SAR Analysis and Design Paradigms
Tetrahydrocarbazole (THCz) is a privileged scaffold validated by clinically approved drugs such as ondansetron, frovatriptan, and ramatroban and exhibits diverse bioactivities including antimicrobial, antitumor, antidiabetic, and neuroprotective effects. Despite extensive structure–activity relationship (SAR) studies, a systematic integration of findings across different therapeutic targets has been lacking. This review provides a comprehensive SAR dissection of THCz derivatives across key targets (bacterial sliding clamp, BTK, HDAC, AMPK, etc.), analyzing how modifications at key positions of the core scaffold (N-9, C-1, and C-6) influence potency and selectivity. Notably, we highlight four emerging design paradigms: pharmacophore hybridization, conformational constraint, cross-target SAR decoding, and precision intervention. By consolidating fragmented knowledge into a practical cross-target SAR matrix, this review offers a strategic framework for the rational design of next-generation THCz-based therapeutics.
- 16 July 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 163, 108747
Fragment-informed SAR: rational construction of quinoline derivatives as dual AChE/BChE inhibitors
- 16 July 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 163, 108747
Fragment-informed SAR: rational construction of quinoline derivatives as dual AChE/BChE inhibitors
- 30 January 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (4) , 1225-1235
Screening of efficient salicylaldoxime reactivators for DFP and paraoxon-inhibited acetylcholinesterase
Dual-site binding mode of lead compounds with AChE and construction of novel salicylaldoxime reactivators using a fragment-based drug design strategy.
- 30 January 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (4) , 1225-1235
Screening of efficient salicylaldoxime reactivators for DFP and paraoxon-inhibited acetylcholinesterase
Dual-site binding mode of lead compounds with AChE and construction of novel salicylaldoxime reactivators using a fragment-based drug design strategy.
- Open Access
Discovery of Novel Non-Oxime Reactivators Showing In Vivo Antidotal Efficiency for Sarin Poisoned Mice
A family of novel efficient non-oxime compounds exhibited promising reactivation efficacy for VX and sarin inhibited human acetylcholinesterase was discovered. It was found that aromatic groups coupled to Mannich phenols and the introduction of imidazole to the ortho position of phenols would dramatically enhance reactivation efficiency. Moreover, the in vivo experiment was conducted, and the results demonstrated that Mannich phenol L10R1 (30 mg/kg, ip) could afford 100% 48 h survival for mice of 2*LD50 sarin exposure, which is promising for the development of non-oxime reactivators with central efficiency.
Open AccessDiscovery of Novel Non-Oxime Reactivators Showing In Vivo Antidotal Efficiency for Sarin Poisoned Mice
A family of novel efficient non-oxime compounds exhibited promising reactivation efficacy for VX and sarin inhibited human acetylcholinesterase was discovered. It was found that aromatic groups coupled to Mannich phenols and the introduction of imidazole to the ortho position of phenols would dramatically enhance reactivation efficiency. Moreover, the in vivo experiment was conducted, and the results demonstrated that Mannich phenol L10R1 (30 mg/kg, ip) could afford 100% 48 h survival for mice of 2*LD50 sarin exposure, which is promising for the development of non-oxime reactivators with central efficiency.
- 1 April 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 215, 113286
Molecular modeling-guided optimization of acetylcholinesterase reactivators: A proof for reactivation of covalently inhibited targets
- 1 April 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 215, 113286
Molecular modeling-guided optimization of acetylcholinesterase reactivators: A proof for reactivation of covalently inhibited targets
- 2 November 2020
- Published by Royal Society of Chemistry (RSC) in Organic Chemistry Frontiers
- Vol. 7 (24) , 4069-4073
A practical strategy to access chiral α-aryloxy carboxylic acids through ion-pairing directed asymmetric hydrogenation
A series of optically active α-aryloxy carboxylic acids were obtained via Chenphos/Rh catalyzed highly efficient asymmetric hydrogenation. The proposed ion-pairing interaction between the ligand and the substrate plays a vital role in achieving high enantioselectivity.
- 2 November 2020
- Published by Royal Society of Chemistry (RSC) in Organic Chemistry Frontiers
- Vol. 7 (24) , 4069-4073
A practical strategy to access chiral α-aryloxy carboxylic acids through ion-pairing directed asymmetric hydrogenation
A series of optically active α-aryloxy carboxylic acids were obtained via Chenphos/Rh catalyzed highly efficient asymmetric hydrogenation. The proposed ion-pairing interaction between the ligand and the substrate plays a vital role in achieving high enantioselectivity.
- 1 July 2020
- Published by Elsevier in Bioorganic Chemistry
- Vol. 100, 103902
Design, synthesis and evaluation of novel nonquaternary and 3 non-oxime reactivators for acetylcholinesterase inhibited by organophosphates
- 1 July 2020
- Published by Elsevier in Bioorganic Chemistry
- Vol. 100, 103902
Design, synthesis and evaluation of novel nonquaternary and 3 non-oxime reactivators for acetylcholinesterase inhibited by organophosphates
- 1 December 2018
- Published by Elsevier in Bioorganic Chemistry
- Vol. 81, 681-688
Design, synthesis and evaluation of new classes of nonquaternary reactivators for acetylcholinesterase inhibited by organophosphates
- 1 December 2018
- Published by Elsevier in Bioorganic Chemistry
- Vol. 81, 681-688
Design, synthesis and evaluation of new classes of nonquaternary reactivators for acetylcholinesterase inhibited by organophosphates
- 1 December 2018
- Published by Elsevier in Bioorganic Chemistry
- Vol. 81, 270-277
Synthesis and biological evaluation of (3′-amino-[1,1′-biphenyl]-4-yl) sulfamic acid derivatives as novel HPTPβ inhibitors
- 1 December 2018
- Published by Elsevier in Bioorganic Chemistry
- Vol. 81, 270-277
Synthesis and biological evaluation of (3′-amino-[1,1′-biphenyl]-4-yl) sulfamic acid derivatives as novel HPTPβ inhibitors